期刊文献+

PPAR-γ对脓毒症炎症机制的研究进展 被引量:2

下载PDF
导出
作者 徐静 王建春
出处 《医学理论与实践》 2009年第4期402-404,共3页 The Journal of Medical Theory and Practice
  • 相关文献

参考文献16

  • 1Moraes LA, PiquerasL, et al. Peroxisome proliferatoractivated activated receptor and inflammation[J]. Phar Ther, 2006, 110 (3) : 371-385.
  • 2姜鹏,王建春,钱桂生.过氧化物酶增殖体激活受体与炎症及免疫反应[J].生命的化学,2005,25(3):232-235. 被引量:8
  • 3刘东,曾邦雄.PPAR-γ受体与急性肺损伤[J].国外医学(麻醉学与复苏分册),2005,26(1):22-25. 被引量:2
  • 4Rieote M, Li AC,Willson TM, et al. The peroxisome proliferator -activated receptor-γ is a negative regulator of macrophage activation[J]. Nature, 1998,391 : 79-82.
  • 5Reddy RC, Keshamouni VG, Jaigirdar SH, et a l. Deactivation of murine alveolar maerophages by peroxisome prollferators-activated receptor γ ligands[J]. Am J Physiol Lung Cell Mol Physiol, 2004,286(3) :L613-L619.
  • 6Hammad H, de Heer HJ, Soullie T, et al. Activation of peroxisome proliferation-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma[J]. American J Pathol, 2004,1641:263.
  • 7Blanquart C, et al. Peroxisome proliferatorsactivated receptors: regulation of transcriptional activities and roles in inflammation[J].J Steroid Biochem MoL, 2003,85 (2-5) : 267-273.
  • 8路一平,邱健.过氧化物酶体增殖物激活受体γ与动脉粥样硬化[J].医学研究生学报,2006,19(6):565-568. 被引量:5
  • 9Straus DS, Pascual G, LiM, et al. 152 Deoxy2△12, 142 prostagland in J2 inhibits multiple steps in the NF- κ B signaling pathway[J]. PNAS, 2002, 97 (5) : 4844-4849.
  • 10Blackwell TS, Christman AN. The role of nueoear factor-kappa B in cytokine grneregulation[J]. Am J Respir Cell Mol Biol, 1997,17(1) :3-9.

二级参考文献44

共引文献15

同被引文献22

  • 1黄建敏,黄瑞雅,郑金瓯,梁志坚.癫癎持续状态并发全身炎症反应综合征致多器官功能障碍综合征患者血清一氧化氮及一氧化氮合酶的变化[J].中国综合临床,2006,22(10):883-885. 被引量:2
  • 2史伟.连续性肾脏替代治疗技术在全身炎症反应综合征的应用[J].中国血液净化,2006,5(9):659-660. 被引量:5
  • 3Ping Xu,Xiao-Jiang Zhou,Ling-Quan Chen,Jiang Chen,Yong Xie,Long-HuaLv,Xiao-Hua Hou.Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis[J].World Journal of Gastroenterology,2007,13(13):1983-1988. 被引量:20
  • 4Levy MM, Fink MP, Marshall JC, et al. 2001 Sc- CWEslCM/ACCP/ATS/SIS international sepsis definitions conference[J]. Cfit Care Med, 2003, 31 (4): 1250-1256.
  • 5Joannidis M. Continuous renal replacement therapy in sepsis and multisystem organ failure[J]. Semin Dial, 2009, 22(2): 160-164.
  • 6GuvenH, Aldntop L, Baydin A, et al. Diagnostic value of proealeitonin levels an early indicator of sepsis[J]. Am J EmergMed, 2002, 20(3): 202- 206.
  • 7Zhang P, Yang Y, Lv R, et al. Effect of the inten- sity of continuous renal replacement therapy in pa- tients with sepsis and acute kidney injury: a single- center randomized clinical trial[J]. Nephrol Dial Transplant, 2012, 27(3): 967-973.
  • 8GuvenH, Aldntop L, Baydin A, et al. value of procalcitonin levels as art early sepsis[J]. Am J Emerg Med, 2002, 20 Diagnostic 202 -206.
  • 9DaIlah AA, EI-Awady GA, RehaI PH, et al. Pro- calcitonin and proinflammalory cytokines clearance during continuous venovenous haemofiltration in septic patients[J].Anaesth Intensive Care, 2002, 30(3): 269-274.
  • 10Meisner M, Huettemann E, Lohs T, et al. Plasma concentration and clearance of procalcitonin during venovenous hemofiltration in septic patients [J]. Shock, 2001, 15(3): 171-175.

引证文献2

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部